Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 4, 2012, Pages 323-334

  Ibarra Lara, Luz ^a,b   Hong, Enrique ^b   Soria Castro, Elizabeth ^a   Torres Narváez, Juan Carlos ^a   Pérez Severiano, Francisca ^c   Del Valle Mondragón, Leonardo ^a   Cervantes Pérez, Luz Graciela ^a   Ramírez Ortega, Margarita ^a   Pastelín Hernández, Gustavo S ^a   Sánchez Mendoza, Alicia ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

angiotensin (1 7); angiotensin II; nitric oxide; superoxide dismutase

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; CATALASE; CLOFIBRATE; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; TETRAHYDROBIOPTERIN;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HEART MUSCLE ISCHEMIA; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIOXIDANTS; CATALASE; CLOFIBRATE; DISEASE MODELS, ANIMAL; HEMODYNAMICS; LIPID PEROXIDATION; MALE; MYOCARDIAL ISCHEMIA; OXIDATIVE STRESS; PPAR ALPHA; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 84867740420     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31826216ed     Document Type: Article

References (59)

1. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol. 2002;34: 1249-1257.
2. Bandyopadhyay D, Chattopadhyay A, Ghosh G, et al. Oxidative stressinduced ischemic heart disease: protection by antioxidants. Curr Med Chem. 2004;11:369-387.
3. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315-424.
4. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47-52.
5. Finkel T. Signal transduction by reactive oxygen species in non phagocytic cells. J Leukoc Biol. 1999;65:337-340.
6. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of the heart failure. Congest Heart Fail. 2002;8:132-140.
7. Hill MF, Signal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation. 1997;96:2414-2420.
8. Lu L, Quinn MT, Sun Y. Oxidative stress in the infarcted heart: role of de novo angiotensin II production. Biochem Biophys Res Commun. 2004; 325:943-951.
9. Nio Y, Matsubara H, Murasawa S, et al. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995;95:46-54.
10. Guellich A, Damy T, Lecarpentier Y, et al. Role of oxidative stress in cardiac dysfunction of PPARa 2/2 mice. Am J Physiol Heart Circ Physiol. 2007;293:H93-H102.
11. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10:238-245.
12. Ibarra-Lara L, Cervantes-Pérez LG, Pérez-Severiano F, et al. PPARa stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner. Eur J Pharmacol. 2010;627: 185-193.
13. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol. 1996;148:291-300.
14. Doring H, Dehnert H. The isolated perfused heart according to Langendorff. Friburgo de Brisgovi, Biomesstechnik-Verlag. 1998;45:1-70.
15. LeBel CP, Bondy CP. Sensitive and rapid quantitation of oxygen reactive species in rat synaptosomes. Neurochem Int. 1990;17:435-440.
16. Spitz DR, Oberley LW. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem. 1989;179:8-18.
17. Crapo JD, McCord JM, Fridovich J. Preparation and assay of superoxide dismutases. Methods Enzymol. 1978;53:382-393.
18. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-126.
19. Sánchez-Mendoza A, Hong E, Escalante B. The role of nitric oxide in angiotensin II-induced renal vasoconstriction in renovascular hypertension. J Hypertens. 1998;16:697-703.
20. Lowry OH, Rosebrough WJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
21. González-Barrios JA, Escalante B, Valdés J, et al. Nitric oxide and nitric oxide synthases in fetal cerebral cortex of rats following transient uteroplacental ischemia. Brain Res. 2002;945:114-122.
22. Janssens SP, Shimouchi T, Quertermous T, et al. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem. 1992;267:14519-14522.
23. Apak R, Guclu K, Ozyurek M. Total antioxidant capacity assay of human serum using copper(II)-neocuproine as chromogenic oxidant: the CUPRAC method. Free Radic Res. 2005;39:949-961.
24. Bahr VP, Basulto LY. The ferric reducing power (FRP). An assay for the serum antioxidant capacity assessment. Correo Científico Médico de Holguín. 2004;8:1-8.
25. Gawron AJ, Lunte SM. Detection of neuropeptides using on-capillary copper complexation and capillary electrophoresis with electrochemical detection. Electrophoresis. 2000;21:3205-3211.
26. González-Morán MG, Soria-Castro E. Histological and stereological studies on Leydig cells in the testes of Gallus domesticus from prehatching to sexual maturity. Anim Reprod Sci. 2010;120:129-135.
27. González-Morán MG, Soria-Castro E. Changes in the tubular compartment of testis of Gallus domesticus during development. Br Poult Sci. 2010;51:296-307.
28. Ferrari R, Ceconi C, Curello S, et al. Myocardial damage during ischemia and reperfusion. Eur Heart J. 1993;14(suppl G):25-30.
29. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA. 1987;84:1404-1407.
30. Goldhaber JI, Ji S, Lamp ST, et al. Effects of exogenous free radicals on electromechanical function and metabolism in isolated rabbit and guinea pig ventricle. Implications for ischemia and reperfusion injury. J Clin Invest. 1989;83:1800-1809.
31. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem. 1998;273: 23786-23792.
32. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of peroxisome proliferator-activated receptors (PPAR-g and PPAR-a) reduce myocardial infarct size. FASEB J. 2002;16:1027-1040.
33. Toba H, Miki S, Shimizu T, et al. The direct antioxidative and antiinflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta. Eur J Pharmacol. 2006;549:124-132.
34. Newaz M, Blanton A, Fidelis P, et al. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)a-mediated cardiovascular effects. Mutat Res. 2005;579:163-171.
35. Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+2superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50:3-11.
36. Loot AE, Rocks AJ, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-1550.
37. Liao XX, Guo RX, Ma H, et al. Effects of angiotensin-(1-7) on oxidative stress and functional changes of isolated rat hearts induced by ischemia-reperfusion. Nan Fang Yi Ke Da Xue Bao. 2008;28:1345-1348.
38. Benter IF, Yousif MH, Dhaunsi GS, et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2008;28:25-33.
39. Berry C, Touyz R, Dominiczak AF, et al. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol. 2001;281:H2337-H2365.
40. Adachi Y, Yoshihiko S, Kishimoto I, et al. Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation. 2003;107:2406-2408.
41. Oishi Y, Ozono R, Yoshizumi M, et al. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci. 2006;80:82-88.
42. Vásquez-Vivar J, Kalynaraman B, Martasek P. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA. 1998;95:9220-9225.
43. Dumitrescu C, Biondi R, Xia Y, et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci USA. 2007;104: 15081-15086.
44. Giraldez R, Panda A, Xia Y, et al. Decreased nitric-oxide synthase activity causes impaired endothelium dependent relaxation in the postischemic heart. J Biol Chem. 1997;272:21420-21426.
45. Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor a agonist increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:658-663.
46. Offstad P, Naess PA, Aksnes G. Nitric oxide regulates coronary blood flow at various coronary arterial pressures in intact porcine hearts. Acta Physiol Scand. 1995;154:93-102.
47. Smith TP, Canty JM. Modulation of coronary autoregulatory responses by nitric oxide. Evidence for flow-dependent resistance adjustments in conscious dogs. Cir Res. 1993;73:232-240.
48. Bulhak AA, Sjoquist PO, Xu CB, et al. Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol. 2006;101: 244-252.
49. Wang Y, Wang Y, Yang Q, et al. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells. Atherosclerosis. 2006;187: 265-273.
50. Tamargo J, Caballero R, Gómez R, et al. Efectos del óxido nítrico sobre la función cardiaca. Rev Esp Cardiol. 2006;6(suppl A):3A-20A.
51. Wang HD, Johns DG, Xu S, et al. Role of superoxide anion in regulating pressor and vascular hypertrophic response to angiotensin II. Am J Physiol. 2002;282:H1697-H1702.
52. Pryor WA, Squadrito GL. The chemistry of peroxinitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol. 1995;268(5 Pt 1): L699-L722.
53. Iwata T, Konno N, Yanagishita T, et al. The role of catalase as a defense mechanism against reperfusion injury. J Mol Cell Cardiol. 1993;25(suppl 1):S104. Abstract.
54. Mehendale H. PPARa: a key to the mechanism of hepatoprotection by clofibrate. Toxicol Sci. 2000;57:187-190.
55. Toyama T, Nakamura H, Harano Y, et al. PPARa ligands activat antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun. 2004;324:697-704.
56. López BL, Liu GL, Christopher TA, et al. Peroxynitrite, the product of nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart. Coron Artery Dis. 1997;8:149-153.
57. Radi R, Beckman JS, Bush KM, et al. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991;288:481-487.
58. Dhalla N, Elmoselhi A, Hata T, et al. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000;47: 446-456.
59. Ruiz Meana M, García-Dorado D. Pathophysiology of ischemia-reperfusion injury: new therapeutic options for acute myocardial infarction. Rev Esp Cardiol. 2009;62:199-209.